肝动脉栓塞化疗联合中药治疗原发性肝癌的疗效观察.doc

1 肝动脉栓塞化疗联合中药治疗原发性肝癌的疗效观察【摘要】目的评价肝动脉栓塞化疗( transcatheter hepatic arterial chemoembolization, TACE ) 联合中药治疗在肝癌中临床价值。方法我科自 2005 年5月— 2007 年10 月,共 62 例肝癌患者接受肝动脉栓塞化疗。所有患者被随机分为两组,其中研究组 38 例,在介入治疗的同期或前后服用中药治疗,对照组 24 例,仅接受肝动脉栓塞化疗。所有患者均接受 2 个或 2 个以上疗程的 TACE 术, 术后定期随访。根据实体瘤的临床疗效评价标准, 2 个疗程 TACE 治疗后进行临床疗效评价。结果 2 个疗程 TACE 术后 1 个月复查 CT 评价临床疗效, 完全缓解( CR )3例, 部分缓解( PR ) 43 例,稳定( SD ) 12 例,进展( PD )4 例,其中研究组 CR 2例, PR 30例, SD 4例, PD 2例, 对照组 CR 1例, PR 13 例, SD 8 例, PD 2 例。中位随访时间 个月, 1 年生存率为 % ( 42/62 ) ,研究组和对照组 1 年生存率分别为 % ( 28/38 )和 % ( 14/24 ) 。治疗过程中大多数毒性都是轻微、一过性的,随访过程中并未发现严重不良事件。在Ⅲ~Ⅳ度的毒性方面,研究组显著低于对照组。结论肝 2 动脉栓塞化疗联合中药治疗肝癌能显著提高临床疗效, 同时降低不良反应的发生率及程度。【关键词】原发性肝癌;肝动脉栓塞化疗;中药 A clinical observation of transcatheter hepatic arterial bined with Chinese materia medica for Primary Liver Cancer 【 Abstract 】 Objective To investigate the clinical value of transcatheter hepatic arterial chemoembolization ( TACE ) combined with Chinese materia medica for primary liver From May 2005 to October 2007, a total of 62 patients with primary liver cancer were recEived TACE. 38 patients with primary liver cancer were assigned to recEIve bined with Chinese materia medica ( experimental group ), while another 24 patients were received TACE alone ( control group ). The effects were evaluated after 2 cycles of TACE according to response evaluation criteria in solid One month after 2 cycles of TACE, computer tomography was carried out to evaluate the response. Complete response ( CR ) was achieved in3 of 62 evaluable patients, 43 3 had partial response ( PR ), 12 had stable disease ( SD ) and 4 had progressive disease ( PD ). In experimental group, CR was seen in2 patients, PR in 30 patients, SD in4 patients and PD in2 patients. While in control group, CR was seen in1 patient, PR in 13 patients, SD in8 patients and PD in2 patients. With a median follow-up of months, 1-year overall survival rate was % ( 42/62 ), % ( 28/38 ) in experimental group and 58.